Japan based Santen Pharmaceutical Co., Ltd. and US based Verily, an Alphabet company, have announced the establishment o...
Japan based Sumitomo Dainippon Pharma Co., Ltd. and UK based Exscientia Ltd. have announced that a phase I clinical stud...
In a recent study researchers at Okayama University, Japan illustrate the potential of berberine, a herbal Chinese medic...
TransEnterix, Inc. a medical device company that is digitizing the interface between the surgeon and the patient to impr...
US based AgeX Therapeutics, a biotechnology company developing therapeutics for human aging and regeneration, announced ...
Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (Torii) have announced that JT has received manufacturing and mark...
Japanese firm Eisai Co., Ltd., has entered into a joint research and development agreement with Personal Genome Diagnost...
Japanese firm Eisai Co., Ltd has obtained the manufacturing and marketing approval in Japan for its in-house discovered ...
Sasakawa Health Foundation has announced the start of its first-ever social media campaign with organizations of persons...
Amgen, Astellas Pharma and Amgen Astellas BioPharma K.K. announced that on April 1, 2020, Amgen will purchase the 49% of...
Japanese firm Eisai Co., Ltd. has obtained the approvals of supplementary new drug applications in Japan for its in-hous...
Swiss firm Ferring Pharmaceuticals has announced that Propess® (dinoprostone) has been approved by the Minister...
POXEL, headquartered France, and with subsidiaries in Japan, is a biopharmaceutical company focused on the development o...
The Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for darolutamide, under th...
Takeda Pharmaceutical Company Limited, headquartered in Japan, is a value-based research-driven biopharmaceutical leader...
Hitachi Chemical Advanced Therapeutics Solutions, LLC, a US subsidiary of Japanese firm Hitachi Chemical Co., Ltd....
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease target...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as share...
